Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021
30 Setembro 2021 - 5:31PM
Business Wire
Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company
committed to discovering and delivering the next generation of
precision cancer medicines, today announced that five abstracts
have been selected for presentation as virtual posters at the
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics on October 7 – 10, 2021.
“The preclinical data being presented today highlight the
potential applicability of synthetic lethal drug targeting across a
range of cancer types. As an example, our lead program, TNG908, an
MTA-cooperative PRMT5 inhibitor selective for cancers with deletion
of the MTAP gene, shows strong regressions across multiple types of
cancer,” said Barbara Weber, M.D., president and Chief Executive
Officer of Tango Therapeutics. “We look forward to leveraging these
data to inform our planned clinical development program.”
Dr. Weber will also be co-chairing an Educational session titled
“Exploiting Synthetic Lethality” on October 7, 2021 at 10:00 AM
ET.
Details on Tango’s presentations at AACR-NCI-EORTC are as
follows:
Poster Title: MTAPnull-selective PRMT5 inhibitors drive
regressions in MTAP-deleted xenograft models across histologies
Abstract #: P214 Date and Time: October 7, 9:00 AM
ET
Poster Title: VRK1 is a novel synthetic lethal target in
VRK2-methylated glioblastoma Abstract #: P182 Date and
Time: October 7, 9:00 AM ET
Poster Title: CRISPR screens identify sensitizers to
Trametinib in KRAS mutant cancer cell lines Abstract #: P183
Date and Time: October 7, 9:00 AM ET
Poster Title: Loss of HS2ST1 cooperates with MAPK
inhibition to impair growth of mesenchymal KRAS mutant NSCLC
Abstract #: P146 Date and Time: October 7, 9:00 AM
ET
Poster Title: Isogenic CRISPR Anchor Screens identified
actionable nodes to CHK1/2 inhibitor Prexasertib in TP53 mutant
cancer Abstract #: P095 Date and Time: October 7,
9:00 AM ET
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to
discovering novel drug targets and delivering the next generation
of precision medicine for the treatment of cancer. Using an
approach that starts and ends with patients, Tango leverages the
genetic principle of synthetic lethality to discover and develop
therapies that take aim at critical targets in cancer. This
includes expanding the universe of precision oncology targets into
novel areas such as tumor suppressor gene loss and their
contribution to the ability of cancer cells to evade immune cell
killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release and the posters
referenced herein may be considered forward-looking statements.
Forward-looking statements generally relate to future events,
Tango’s future operating performance, goals, expectations, beliefs
and development objectives for Tango’s product pipeline. In some
cases, you can identify forward-looking statements by terminology
such as “may”, “should”, “expect”, “intend”, “will”, “goal”,
“estimate”, “anticipate”, “believe”, “predict”, “potential” or
“continue”, or the negatives of these terms or variations of them
or similar terminology. For example, statements concerning the
following include or constitute forward-looking statements: the
data presented highights the potential applicability of synthetic
lethal drug targeting across a range of approaches for the
treatment of cancers; the potential benefits of the synthetic
lethal approach to treating cancer; the Company will leverage these
data to inform its planned clinical development program; Tango’s
ability to identify, develop and commercialize drug candidates; the
future anticipated benefits of product candidates (including
TNG908) identified through the Tango discovery platform; and the
expected timing of: (i) development candidate declaration for
certain targets, (ii) initiating IND-enabling studies; (iii) filing
INDs and (iv) clinical trial initiation. Such forward-looking
statements are subject to risks, uncertainties, and other factors
which could cause actual results to differ materially from those
expressed or implied by such forward looking statements. These
forward-looking statements are based upon estimates and assumptions
that, while considered reasonable by Tango and its management are
inherently uncertain. New risks and uncertainties may emerge from
time to time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: Tango has a limited operating history and has not generated any
revenue to date from drug sales, and may never become profitable;
Tango will need to raise capital in the future and if we are unable
to raise capital when needed or on attractive terms, we would be
forced to delay, scale back or discontinue some of our development
programs or future commercialization efforts; we may be unable to
advance our preclinical development programs into and through the
clinic for safety or efficacy reasons or commercialize our product
candidates or we may experience significant delays in doing so as a
result of factors beyond Tango’s control; Tango’s approach to the
discovery and development of product candidates is novel and
unproven, which makes it difficult to predict the time, cost of
development, and likelihood of successfully developing any
products; Tango may not identify or discover additional product
candidates or may expend limited resources to pursue a particular
product candidate or indication and fail to capitalize on product
candidates or indications that may be more profitable or for which
there is a greater likelihood of success; our products candidates
may cause adverse or other undesirable side effects that could,
among other things, delay or prevent regulatory approval; our
dependence on third parties for conducting clinical trials and
producing drug product; our ability to obtain and maintain patent
and other intellectual property protection for our technology and
product candidates or the scope of intellectual property protection
obtained is not sufficiently broad; and delays and other impacts on
product development and clinical trials from the COVID-19 pandemic.
Additional information concerning risks, uncertainties and
assumptions can be found in Tango’s filings with the SEC, including
the risk factors referenced in Tango’s Current Report on Form 8-K
filed with the SEC on August 13, 2021. You should not place undue
reliance on forward-looking statements in this presentation, which
speak only as of the date they are made and are qualified in their
entirety by reference to the cautionary statements herein. Tango
specifically disclaims any duty to update these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210930005136/en/
Investor Contact: Sam Martin Argot Partners
tango@argotpartners.com
Media Contact: Joshua R. Mansbach Argot Partners
tango@argotpartners.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024